283 related articles for article (PubMed ID: 18428082)
1. Can we help one billion sick people?
Maliski E; Gund P; Brown F
Curr Opin Drug Discov Devel; 2008 May; 11(3):301-2. PubMed ID: 18428082
[No Abstract] [Full Text] [Related]
2. Mission possible.
Hopkins AL; Witty MJ; Nwaka S
Nature; 2007 Sep; 449(7159):166-9. PubMed ID: 17851512
[No Abstract] [Full Text] [Related]
3. Developing drugs for developing countries.
Ridley DB; Grabowski HG; Moe JL
Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
[TBL] [Abstract][Full Text] [Related]
4. Prioritising neglected diseases related to poverty.
MacDonald R
BMJ; 2005 Jul; 331(7507):12. PubMed ID: 15994687
[TBL] [Abstract][Full Text] [Related]
5. Support system: through charities, drug makers help people--and themselves.
Anand G
Wall St J (East Ed); 2005 Dec; ():A1, A10. PubMed ID: 16502554
[No Abstract] [Full Text] [Related]
6. CMS move threatens to put orphan drugs out in cold.
Carroll J
Manag Care; 2003 Jul; 12(7):10-1. PubMed ID: 12891947
[No Abstract] [Full Text] [Related]
7. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
8. [Infectiology and tropical medicine -- new developments 2006].
Reisinger EC; Burchard GD
Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1474-8. PubMed ID: 16794980
[No Abstract] [Full Text] [Related]
9. Discontinued drugs in 2008: anti-infectives.
Ryder NS
Expert Opin Investig Drugs; 2010 Jan; 19(1):1-21. PubMed ID: 20001552
[TBL] [Abstract][Full Text] [Related]
10. Eliminating neglected diseases: impact of published paper.
Brownback S
Health Aff (Millwood); 2007; 26(5):1509. PubMed ID: 17848471
[No Abstract] [Full Text] [Related]
11. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
12. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
13. Therapeutic breakthroughs in the millennium: what to look for in the next two decades. Part 2: New therapeutics reverse old thinking.
Davidson S
Health Forum J; 1999; 42(2):61-3. PubMed ID: 10538905
[No Abstract] [Full Text] [Related]
14. Remedies for tropical diseases.
Garattini S
Lancet; 1988 Jun; 1(8598):1338. PubMed ID: 2897585
[No Abstract] [Full Text] [Related]
15. View from the Nation's Capital.
Freishtat HW
J Clin Psychopharmacol; 1985 Apr; 5(2):117-9. PubMed ID: 3988970
[No Abstract] [Full Text] [Related]
16. The path to new medicines.
Callan B; Gillespie I
Nature; 2007 Sep; 449(7159):164-5. PubMed ID: 17851511
[No Abstract] [Full Text] [Related]
17. The Orphan Drug Act: an engine of innovation? At what cost?
Rohde DD
Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
[No Abstract] [Full Text] [Related]
18. Orphan economics: the downside of supplyside pharmacology.
Samson K
Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
[No Abstract] [Full Text] [Related]
19. What is wrong with orphan drug policies?
Côté A; Keating B
Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
[TBL] [Abstract][Full Text] [Related]
20. The use of oral antibiotics in lower-extremity infections.
Joseph WS; Lefrock J
Clin Podiatr Med Surg; 1996 Oct; 13(4):683-99. PubMed ID: 8902339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
